A National Institutes of Health-led national trial demonstrated that ipilimumab, which targets the CTLA-4 protein, and nivolumab combined with the adjuvant TMZ were safe and tolerable in patients with newly diagnosed GBM. This evidence concerns the gene CTLA4 and glioblastoma.